Marker Therapeutics, Inc. - MRKR STOCK NEWS

Marker Therapeutics (Nasdaq: MRKR) announces the opening of its new cGMP manufacturing facility in Houston, TX. This facility will support the Phase 2 acute myeloid leukemia (AML) trial, aiming to enroll 160 patients. The modular facility, spanning 48,500 square feet and currently utilizing a third of its space, represents a strategic goal to enhance therapy access and reduce manufacturing costs. This development is crucial for the company's MultiTAA-specific T cell products, aiming to facilitate future clinical trials and potential commercialization of approved products.

Marker Therapeutics, Inc. (Nasdaq:MRKR) announced the completion of the six-patient safety lead-in phase of its Phase 2 trial for MT-401, targeting post-transplant acute myeloid leukemia (AML). All participants met safety endpoints following treatment with the MultiTAA-specific T cell therapy. The ongoing trial aims to evaluate MT-401's efficacy against AML in both adjuvant and active disease settings, with a total of approximately 160 patients involved. The FDA previously granted Orphan Drug designation to MT-401, highlighting its potential in addressing unmet needs in AML treatment.

Marker Therapeutics, Inc. (NASDAQ: MRKR) announced that Chief Financial Officer Anthony H. Kim will present at the virtual Raymond James Human Health Innovation Conference on June 21, 2021, at 9:20 a.m. ET. Marker Therapeutics is focused on developing next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumors. The presentation will be available via a live webcast on their website and can be replayed afterward. The company's innovative approach emphasizes non-engineered, tumor-specific T cells, potentially reducing manufacturing costs and toxicities while enhancing patient outcomes.

Marker Therapeutics, Inc. (Nasdaq:MRKR) reported its Q1 2021 financial results, highlighting a net loss of $8.8 million compared to $6.5 million in Q1 2020. The company closed a public offering raising approximately $56.5 million, strengthening its cash position to $64.5 million, sufficient to fund operations into Q1 2023. Significant advancements include dosing the first patient in a Phase 2 trial for AML and the operationalization of a new cGMP facility. Expected milestones include initiating the main trial phase in Q3 2021 and completing patient enrollment by Q4 2021.

Marker Therapeutics, Inc. (Nasdaq:MRKR) will host a conference call and webcast on May 12, 2021, at 5:00 p.m. ET to discuss its first quarter 2021 financial results and provide a corporate update. Participants can join via the company's website or by calling 877-407-8913 (domestic) or 201-689-8201 (international). After the event, the archived webcast will be available for replay. Marker Therapeutics specializes in developing T cell-based immunotherapies for hematological malignancies and solid tumors, claiming advantages over current engineered therapies.

Marker Therapeutics (Nasdaq:MRKR) announced the presentation of new robotics technology for manufacturing multi-tumor-associated antigen (mTAA)-specific T cell therapies at the ASGCT Annual Meeting from May 11-14, 2021. Lead author Anastasiya Smith, Ph.D., will discuss a robotic assistant prototype, co-designed with ABB Robotics, which demonstrated superior precision in liquid handling compared to human operators. This innovation aims to simplify processes and enhance the availability of cell therapies to a broader patient population, particularly for treating hematological cancers like acute myeloid leukemia (AML).

Marker Therapeutics, Inc. (Nasdaq: MRKR) has completed an underwritten public offering of 32,282,857 shares of common stock at a price of $1.75 per share, generating approximately $56.5 million in gross proceeds. The offering, managed by Piper Sandler & Co., Cantor Fitzgerald & Co., and Oppenheimer & Co. Inc., was conducted under a shelf registration statement declared effective by the SEC on June 25, 2019. The funds raised are expected to support the company’s development of T cell-based immunotherapies for hematological malignancies and solid tumors.

Marker Therapeutics, Inc. (NASDAQ:MRKR) announced that President and CEO Peter L. Hoang will present at the Virtual Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 3:10 p.m. ET. This clinical-stage immuno-oncology company focuses on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors. A live webcast of the presentation will be accessible on Marker’s website, with a replay available afterwards.

Marker Therapeutics, Inc. (Nasdaq: MRKR) has announced the pricing of an underwritten public offering of 28,572,000 shares at $1.75 each, aiming to raise approximately $50 million before expenses. A 30-day option for underwriters to purchase an additional 4,285,800 shares has been granted. The offering, managed by Piper Sandler & Co. and Cantor Fitzgerald & Co., is expected to close around March 16, 2021, subject to customary conditions. This transaction is part of a shelf registration statement effective since June 25, 2019.